EQT Concludes Successful Sale of Shares in Galderma Group AG

EQT Completes Share Placement in Galderma

EQT, through its affiliate EQT VIII, has successfully completed the sale of 17 million shares in Galderma Group AG, a prominent player in the dermatology industry. This significant transaction yielded gross proceeds of approximately CHF 2.1 billion, reinforcing EQT's robust investment strategy.

The placement was carried out via an accelerated bookbuilding process, a method that allows investors to gauge demand quickly in a fast-moving environment. The transaction was coordinated by leading financial institutions, namely BNP Paribas, Citigroup Global Markets, Goldman Sachs, Jefferies, Morgan Stanley, and UBS, who facilitated the smooth execution of this complex deal.

EQT's financial gain from this operation amounted to approximately CHF 555 million, a substantial return that underscores the value being generated from its investments. Completed on July 31, 2025, this sale marks a significant milestone in EQT’s ongoing efforts to optimize its investment portfolio and realize the returns from its stake in Galderma Group AG.

Galderma, listed under SIX GALD, has been recognized for its innovative solutions in skin health and dermatological products. The company has a strong market presence, driven by its commitment to research and development, ensuring that it stays ahead of trends within the health and personal care industries.

This strategic move by EQT not only enhances the company’s liquidity, enabling potential new acquisitions or investments but also signals confidence in the continued growth of the dermatology sector. As consumer interest continues to rise in skincare and dermatological treatments, EQT’s investment strategy appears well-aligned with market demands.

In conclusion, EQT’s successful share placement illustrates its proactive approach to investment management and its aptitude for seizing opportunities in the financial markets. Existing and potential investors will be keeping a close watch on the impacts of this sale on both EQT and Galderma as it unfolds in the coming months.